Can mouse models for brain tumors inform treatment in pediatric patients?

Seminars in Cancer Biology

Volumn 14, Issue 1, 2004, Pages 71-77

  Weiss, William A ^a   Banerjee, Anu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mouse models of cancer; Pediatric brain tumors; Targeted therapies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN; TEMOZOLOMIDE; TIPIFARNIB;

ANIMAL MODEL; BRAIN CANCER; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INFILTRATION; CANCER MODEL; CHILDHOOD CANCER; DISEASE EXACERBATION; EXPERIMENTAL MODEL; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; NONHUMAN; ONCOGENE RAS; PROGNOSIS; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; TISSUE SECTION; TUMOR RECURRENCE; XENOGRAFT;

EID: 0842329751     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.11.008     Document Type: Article

References (46)

1. Strother DP, Gisher PG, Hunter JV, Woo SY, Pomeroy SL, Rorke LB. Tumors of the central nervous system. In: Pizzo PP, editor. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 751-824.
2. Rubin J.B., Rowitch D.H. Medulloblastoma: a problem of developmental biology. Cancer Cell. 2(1):2002;7-8.
3. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61(3):215-25 [discussion, 26-9].
4. Sposto R., Ertel I.J., Jenkin R.D., Boesel C.P., Venes J.L., Ortega J.A.et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children, results of a randomized trial. A report from the Childrens Cancer Study Group. J. Neurooncol. 7:1989;165-177.
5. Finlay J.L., Boyett J.M., Yates A.J., Wisoff J.H., Milstein J.M., Geyer J.R.et al. Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight-drugs-in-one-day regimen. J. Clin. Oncol. 13:1995;112-123.
6. Albright A.L., Guthkelch A.N., Packer R.J., Price R.A., Rourke L.B. Prognostic factors in pediatric brain-stem gliomas. J. Neurosurg. 65(6):1986;751-755.
7. Freeman C.Ra.J.P.F. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol. 40(2):1998;265-271.
8. Campbell J.W., Pollack I.F., Martinez A.J., Shultz B. High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery. 38(2):1996;258-264.
9. Pollack IF, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, et al., the Children's Cancer Group. Expression of p53 and Prognosis in Children with Malignant Gliomas. N Engl J Med 2002;346(6):420-6.
10. Pollack IF, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Finlay JL, et al., the Children's Cancer Group. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 2001;61:7404-7.
11. Bredel M.P., Ian F., Hamilton R.L., James C.D. Epidermal growth factor receptor expression and gene amplification in high grade non-brainstem gliomas of childhood. Clin. Cancer Res. 5:1999;1786-1792.
12. Raffel C.F.L., O'Fallon J.R., Atherton-Skaff P., Perry A., Jenkins R.B., James C.D. Analysis of oncogene and tumor suppressor gene alterarations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin. Cancer Res. 5:1999;4085-4090.
13. Zhou X.P., Li Y.J., Hoang-Xuan K., Laurent-Puig P., Mokhtari K., Longy M.et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer. 84:1999;150-154.
14. Maxwell M.N.S.P., Wolfe H.J. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J. Clin. Invest. 86:1990;131-140.
15. Vassbotn F.O.A., Langeland N., Holmsen H., Westermark B., Heldin C.-H., Nister M. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J. Cell Physiol. 158:1994;381-389.
16. Mauro A.B.A., Turco E., Schiffer D. Co-expression of platelet-derived growth factor (PDGF) B chain and PDGF B type receptor in human gliomas. Child Nerv Syst. 7:1991;432-436.
17. Bredel M.P., Ian F. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res. Rev. 29(2/3):1999;232-249.
18. Stupp R.D.P.Y., Ostermann Kraljevic S., Pica A., Maillard I., Maeder P., Meuli R.et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Onocol. 20(5):2002;1375-1382.
19. Grossman S.O.N.A., Grunnet M., Mehta M., Pearlman J.L., Wagner H., Gilbert M.et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme, Eastern Cooperative Oncology 2394. J. Clin. Oncol. 21(8):2003;1485-1491.
20. Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P.G.et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA. 94(6):1997;2551-2556.
21. He L.Z., Tribioli C., Rivi R., Peruzzi D., Pelicci P.G., Soares V.et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA. 94(10):1997;5302-5307.
22. Grisolano J.L., Wesselschmidt R.L., Pelicci P.G., Ley T.J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood. 89(2):1997;376-387.
23. Wolff N.C., Ilaria R.L. Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 98(9):2001;2808-2816.
24. Dash A.B., Williams I.R., Kutok J.L., Tomasson M.H., Anastasiadou E., Lindahl K.et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA. 99(11):2002;7622-7627.
25. Ding H., Roncari L., Shannon P., Wu X., Lau N., Karaskova J.et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 61(9):2001;3826-3836.
26. Xiao A., Wu H., Pandolfi P.P., Louis D.N., Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1(2):2002;157-168.
27. Weiss W.A., Burns M.J., Hackett C., Aldape K., Hill J.R., Kuriyama H.et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 63(7):2003;1589-1595.
28. Holland E.C., Hively W.P., DePinho R.A., Varmus H.E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12(23):1998;3675-3685.
29. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 25(1):2000;55-57.
30. Jensen N.A., Pedersen K.M., Lihme F., Rask L., Nielsen J.V., Rasmussen T.E.et al. Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. J Biol Chem. 278(10):2003;8300-8308.
31. Reilly K.M., Loisel D.A., Bronson R.T., McLaughlin M.E., Jacks T. Nf1, Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 26(1):2000;109-113.
32. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 351(Pt 1):2000;95-105.
33. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J. 371(Pt 1):2003;199-204.
34. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298(5600):2002;1912- 1934.
35. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P.et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307(5951):1984;521-527.
36. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A.et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 6(9):2000;1024-1028.
37. Ritland S.R., Gendler S.J., Burgart L.J., Fry D.W., Nelson J.M., Bridges A.J.et al. Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury. Cancer Res. 60(17):2000;4678-4681.
38. Roberts R.B., Min L., Washington M.K., Olsen S.J., Settle S.H., Coffey R.J.et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA. 99(3):2002;1521-1526.
39. Bishop A.C., Buzko O., Shokat K.M. Magic bullets for protein kinases. Trends Cell Biol. 11(4):2001;167-172.
40. Fan Q.W., Zhang C., Shokat K.M., Weiss W.A. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr Biol. 12(16):2002;1386-1394.
41. Busse D., Doughty R.S., Ramsey T.T., Russell W.E., Price J.O., Flanagan W.M.et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem. 275(10):2000;6987-6995.
42. Sherr C.J., DePinho R.A. Cellular senescence: mitotic clock or culture shock? Cell. 102(4):2000;407-410.
43. Jones H.A., Hahn S.M., Bernhard E., McKenna W.G. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 11(4):2001;328-337.
44. Bernhard E.J., Kao G., Cox A.D., Sebti S.M., Hamilton A.D., Muschel R.J.et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56(8):1996;1727-1730.
45. Bernhard E.J., McKenna W.G., Hamilton A.D., Sebti S.M., Qian Y., Wu J.M.et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58(8):1998;1754-1761.
46. Delmas C., Heliez C., Cohen-Jonathan E., End D., Bonnet J., Favre G.et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer. 100(1):2002;43-48.